T-cell tolerance in cancer

Immunotherapy

Volumn 5, Issue 5, 2013, Pages 513-531

  Nurieva, Roza ^a   Wang, Junmei ^a   Sahoo, Anupama ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

costimulation; E3 ubiquitin ligase; epigenetics; immune tolerance; transcription; tumor

Indexed keywords

CBL B PROTEIN; DENILEUKIN DIFTITOX; GRAIL PROTEIN; ITCH PROTEIN; STAT3 PROTEIN; TUMOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CELL STIMULATION; CYTOTOXICITY; DENDRITIC CELL; EPIGENETICS; GENETIC REGULATION; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE; MACROPHAGE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; TUMOR IMMUNITY;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; IMMUNE TOLERANCE; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 84877257306     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.33     Document Type: Article

References (263)

1. Schwartz RH. T cell anergy. Annu. Rev. Immunol. 21(1), 305-334 (2003).
2. Mueller DL, Jenkins MK, Schwartz R. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7(1), 445-480 (1989).
3. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20(1), 197-216 (2002).
4. Dong C, Nurieva RI. Regulation of immune and autoimmune responses by ICOS. J. Autoimmun. 21(3), 255-260 (2003).
5. Nurieva R, Thomas S, Nguyen T et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J. 25(11), 2623-2633 (2006).
6. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6(11), 1133-1141 (2005).
7. Sharpe A. Costimulation and regulation of autoimmunity and tolerance. J. Pediat. Gastroenterol. Nutr. 40, S20-S21 (2005).
8. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
9. Kryczek I, Zou L, Rodriguez P et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203(4), 871-881 (2006).
10. Hirano F, Kaneko K, Tamura H et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65(3), 1089-1096 (2005).
11. Krambeck AE, Thompson RH, Dong HD et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl Acad. Sci. USA 103(27), 10391-10396 (2006).
12. Tringler B, Liu W, Corral L et al. B7-H4 overexpression in ovarian tumors. Gynecol. Oncol. 100(1), 44-52 (2006).
13. Castriconi R, Dondero A, Augugliaro R et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc. Natl Acad. Sci. USA 101(34), 12640-12645 (2004).
14. Mueller DL. E3 ubiquitin ligases as T cell anergy factors. Nat. Immunol. 5(9), 883-890 (2004).
15. Heissmeyer V, Macián F, Im SH et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat. Immunol. 5(3), 255-265 (2004).
16. Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO Rep. 9(1), 50-55 (2008).
17. Jeon MS, Atfield A, Venuprasad K et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21(2), 167-177 (2004).
18. Safford M, Collins S, Lutz MA et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 6(5), 472-480 (2005).
19. Wells AD. New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting. J. Immunol. 182(12), 7331-7341 (2009).
20. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 133(5), 775-787 (2008).
21. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564 (2012).
22. Smith TR, Kumar V. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 29(7), 337-342 (2008).
23. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 241(1), 104-118 (2011).
24. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
25. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3(11), 999-1005 (2002).
26. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
27. Takahashi H, Feuerhake F, Kutok JL et al. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin. Cancer Res. 12(11 Pt 1), 3265-3271 (2006).
28. Shin MS, Kim HS, Lee SH et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 61(13), 4942-4946 (2001).
29. Hinz S, Trauzold A, Boenicke L et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis. Oncogene 19(48), 5477-5486 (2000).
30. Bots M, Kolfschoten IG, Bres SA et al. SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. Blood 105(3), 1153-1161 (2005).
31. Yamamoto R, Nishikori M, Kitawaki T et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111(6), 3220-3224 (2008).
32. Agaugue S, Carosella ED, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 117(26), 7021-7031 (2011).
33. Derre L, Corvaisier M, Charreau B et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J. Immunol. 177(5), 3100-3107 (2006).
34. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5(1), 29-41 (2005).
35. Favier B, Lemaoult J, Lesport E, Carosella ED. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J. 24(3), 689-699 (2010).
36. Lee N, Llano M, Carretero M et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl Acad. Sci. USA 95(9), 5199-5204 (1998).
37. Gooden M, Lampen M, Jordanova ES et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc. Natl Acad. Sci. USA 108(26), 10656-10661 (2011).
38. Garcia P, Llano M, De Heredia AB et al. Human T cell receptor-mediated recognition of HLA-E. Eur. J. Immunol. 32(4), 936-944 (2002).
39. Chung CD, Patel VP, Moran M, Lewis LA, Miceli MC. Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol. 165(7), 3722-3729 (2000).
40. Ilarregui JM, Croci DO, Bianco GA et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10(9), 981-991 (2009).
41. Okudaira K, Hokari R, Tsuzuki Y et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int. J. Oncol. 35(4), 741-749 (2009).
42. Rubinstein N, Alvarez M, Zwirner NW et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5(3), 241-251 (2004).
43. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24, 99-146 (2006).
44. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 downregulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am. J. Pathol. 165(6), 1853-1863 (2004).
45. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096-1103 (1996).
46. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9(10), 1269-1274 (2003).
47. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoid-like stroma and immune escape by tumors that express the chemokine CCL21. Science 328(5979), 749-752 (2010).
48. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162-174 (2009).
49. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004).
50. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33(3), 119-126 (2012).
51. Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC. The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat. Rev. Immunol. 7(3), 231-237 (2007).
52. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445(7129), 766-770 (2007).
53. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8(3), 277-284 (2007).
54. Gavin MA, Rasmussen JP, Fontenot JD et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445(7129), 771-775 (2007).
55. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22(3), 329-341 (2005).
56. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003).
57. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609), 1057-1061 (2003).
58. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20-21 (2001).
59. Brunkow ME, Jeffery EW, Hjerrild KA et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27(1), 68-73 (2001).
60. Kobayashi I, Shiari R, Yamada M et al. Novel mutations of FOXP3 in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX). J. Med. Genet. 38(12), 874-876 (2001).
61. Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of FOXP3+ regulatory T cells. J. Immunol. 178(1), 280-290 (2007).
62. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6(11), 1142-1151 (2005).
63. Burchill MA, Yang J, Vang KB, Farrar MA. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol. Lett. 114(1), 1-8 (2007).
64. Yao Z, Kanno Y, Kerenyi M et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109(10), 4368-4375 (2007).
65. Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S, Chen W. A critical function for TGF-beta signaling in the development of natural CD4+CD25+FOXP3+ regulatory T cells. Nat. Immunol. 9(6), 632-640 (2008).
66. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J. Exp. Med. 201(7), 1061-1067 (2005).
67. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25(3), 455-471 (2006).
68. Meloni F, Morosini M, Solari N et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28-T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum. Immunol. 67(1-2), 1-12 (2006).
69. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169(5), 2756-2761 (2002).
70. Ding Y, Xu J, Bromberg JS. Regulatory T cell migration during an immune response. Trends Immunol. 33(4), 174-180 (2012).
71. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer 6(8), 613-625 (2006).
72. Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over FOXP3+ regulatory T cell function. Science 322(5899), 271-275 (2008).
73. Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak-Rothstein A, Abbas AK. Response to self antigen imprints regulatory memory in tissues. Nature 480(7378), 538-542 (2011).
74. Foss FM. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin. Lymphoma 1(2), 110-116; discussion: 117 (2000).
75. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005).
76. Gritzapis AD, Voutsas IF, Baxevanis CN. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice. Cancer Immunol. Immunother. 61(3), 397-407 (2012).
77. Salagianni M, Lekka E, Moustaki A et al. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J. Immunol. 186(6), 3327-3335 (2011).
78. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67(9), 4507-4513 (2007).
79. Pan PY, Wang GX, Yin B et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111(1), 219-228 (2008).
80. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64(17), 6337-6343 (2004).
81. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67(20), 10019-10026 (2007).
82. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166(1), 678-689 (2001).
83. Ugel S, Peranzoni E, Desantis G et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2(3), 628-639 (2012).
84. Nefedova Y, Huang M, Kusmartsev S et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172(1), 464-474 (2004).
85. Cheng P, Corzo CA, Luetteke N et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205(10), 2235-2249 (2008).
86. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181(7), 4666-4675 (2008).
87. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65(20), 9525-9535 (2005).
88. Fujita M, Zhu X, Sasaki K et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J. Immunol. 180(4), 2089-2098 (2008).
89. Vasquez-Dunddel D, Pan F, Zeng Q et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. 123(4) 1580-1589 (2013).
90. Marigo I, Bosio E, Solito S et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32(6), 790-802 (2010).
91. Greifenberg V, Ribechini E, Rossner S, Lutz MB. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 39(10), 2865-2876 (2009).
92. Mandruzzato S, Solito S, Falisi E et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182(10), 6562-6568 (2009).
93. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181(8), 5791-5802 (2008).
94. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by l-arginine. J. Biol. Chem. 277(24), 21123-21129 (2002).
95. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160(12), 5729-5734 (1998).
96. Harari O, Liao JK. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr. Pharm. Des. 10(8), 893-898 (2004).
97. Rivoltini L, Carrabba M, Huber V et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev. 188, 97-113 (2002).
98. Bronte V, Kasic T, Gri G et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201(8), 1257-1268 (2005).
99. Nagaraj S, Gupta K, Pisarev V et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13(7), 828-835 (2007).
100. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172(2), 989-999 (2004).
101. Yang R, Cai Z, Zhang Y, Yutzy WH 4th, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 66(13), 6807-6815 (2006).
102. Huang B, Pan PY, Li Q et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66(2), 1123-1131 (2006).
103. Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92(11), 4150-4166 (1998).
104. Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92(12), 4778-4791 (1998).
105. Young MR, Wright MA, Young ME. Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells. Cancer Immunol. Immunother. 33(3), 146-152 (1991).
106. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159(10), 4772-4780 (1997).
107. Sharma S, Stolina M, Lin Y et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 163(9), 5020-5028 (1999).
108. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170(7), 3488-3494 (2003).
109. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61(1), 363-369 (2001).
110. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9(11), 798-809 (2009).
111. Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10(1), 48-54 (2004).
112. Yu Z, Zhang W, Kone BC. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem. J. 367(Pt 1), 97-105 (2002).
113. Hoentjen F, Sartor RB, Ozaki M, Jobin C. STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. Blood 105(2), 689-696 (2005).
114. Stoitzner P, Green LK, Jung JY et al. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol. Immunother. 57(11), 1665-1673 (2008).
115. Cheng C, Qu QX, Shen Y et al. Overexpression of B7-H4 in tumor infiltrated dendritic cells. J. Immunoassay Immunochem. 32(4), 353-364 (2011).
116. Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin. Dev. Immunol. 2011, 430394 (2011).
117. Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202(7), 919-929 (2005).
118. Mizutani K, Sud S, McGregor NA et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11(11), 1235-1242 (2009).
119. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro. Oncol. 8(3), 261-279 (2006).
120. Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system immunity and glioma immunology. J. Clin. Neurosci. 17(1), 6-10 (2010).
121. Movahedi K, Laoui D, Gysemans C et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70(14), 5728-5739 (2010).
122. Molon B, Ugel S, Del Pozzo F et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208(10), 1949-1962 (2011).
123. Lu T, Ramakrishnan R, Altiok S et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121(10), 4015-4029 (2011).
124. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004).
125. Mitchem JB, Brennan DJ, Knolhoff BL et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73(3), 1128-1141 (2013).
126. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin. Cancer Res. 7(11), 3540-3543 (2001).
127. Frauwirth KA, Alegre M-L, Thompson CB. Induction of T cell anergy in the absence of CTLA-4/B7 interaction. J. Immunol. 164(6), 2987-2993 (2000).
128. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity 14(2), 145-155 (2001).
129. Filatenkov AA, Jacovetty EL, Fischer UB, Curtsinger JM, Mescher MF, Ingulli E. CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance. J. Immunol. 174(11), 6909-6917 (2005).
130. Fathman CG, Lineberry NB. Molecular mechanisms of CD4+ T-cell anergy. Nat. Rev. Immunol. 7(8), 599-609 (2007).
131. Boise LH, Minn AJ, Noel PJ et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3(1), 87-98 (1995).
132. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224(1), 166-182 (2008).
133. Borriello F, Sethna MP, Boyd SD et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6(3), 303-313 (1997).
134. Girvin AM, Dal Canto MC, Rhee L et al. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J. Immunol. 164(1), 136-143 (2000).
135. Schweitzer AN, Sharpe AH. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J. Immunol. 161(6), 2762-2771 (1998).
136. Shahinian A, Pfeffer K, Lee KP et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261(5121), 609 (1993).
137. Tada Y, Nagasawa K, Ho A et al. CD28-deficient mice are highly resistant to collagen-induced arthritis. J. Immunol. 162(1), 203-208 (1999).
138. Dong C, Juedes AE, Temann UA et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409(6816), 97-101 (2001).
139. Hutloff A, Dittrich AM, Beier KC et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 402, 21-24 (1999).
140. Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7. 1 and B7. 2, is induced by TNFalpha. Immunity 11(4), 423-432 (1999).
141. Nurieva RI, Duong J, Kishikawa H et al. Transcriptional regulation of th2 differentiation by inducible costimulator. Immunity 18(6), 801-811 (2003).
142. Nurieva RI, Mai XM, Forbush K, Bevan MJ, Dong C. B7h is required for T cell activation, differentiation, and effector function. Proc. Natl Acad. Sci. USA 100(24), 14163-14168 (2003).
143. Young DA, Hegen M, Ma HLM et al. Blockade of the interleukin-21/ interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56(4), 1152-1163 (2007).
144. Nurieva RI, Chung Y, Hwang D et al. Generation of follicular helper T cells is mediated by IL-21 but independent of TH1, TH2 or TH17 lineages. Immunity 29(1), 138 (2008).
145. Gotsman I, Grabie N, Gupta R et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114(19), 2047-2055 (2006).
146. Akbari O, Freeman GJ, Meyer EH et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8(9), 1024-1032 (2002).
147. Massey EJ, Sundstedt A, Day MJ, Corfield G, Anderton S, Wraith DC. Intranasal peptide-induced peripheral tolerance: the role of IL-10 in regulatory T cell function within the context of experimental autoimmune encephalomyelitis. Vet. Immunol. Immunopathol. 87(3), 357-372 (2002).
148. Faria A, Maron R, Ficker SM, Slavin AJ, Spahn T, Weiner HL. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J. Autoimmun. 20(2), 135-145 (2003).
149. Miyamoto K, Kingsley CI, Zhang X et al. The ICOS molecule plays a crucial role in the development of mucosal tolerance. J. Immunol. 175(11), 7341-7347 (2005).
150. Suresh M, Whitmire JK, Harrington LE et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J. Immunol. 167(10), 5565-5573 (2001).
151. Bertram EM, Tafuri A, Shahinian A et al. Role of ICOS versus CD28 in antiviral immunity. Eur. J. Immunol. 32(12), 3376-3385 (2002).
152. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr. Opin. Cell Biol. 11(2), 203-210 (1999).
153. Read S, Greenwald R, Izcue A et al. Blockade of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo. J. Immunol. 177(7), 4376-4383 (2006).
154. Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11(2), 728-734 (2005).
155. Hurwitz AA, Foster BA, Kwon ED et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60(9), 2444-2448 (2000).
156. Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96(26), 15074-15079 (1999).
157. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996).
158. Waitz R, Solomon SB, Petre EN et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72(2), 430-439 (2012).
159. Fong L, Kwek SS, O'Brien S et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA-4 blockade and GM-CSF. Cancer Res. 69(2), 609-615 (2009).
160. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
161. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu. Rev. Immunol. 23, 515-548 (2005).
162. Chen Y, Zhang J, Li J et al. Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp. Nephrol. 102(3-4), e81-e92 (2006).
163. De Haij S, Woltman AM, Trouw LA et al. Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. Kidney Int. 68(5), 2091-2102 (2005).
164. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169(7), 3581-3588 (2002).
165. Yamazaki T, Akiba H, Iwai H et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169(10), 5538-5545 (2002).
166. Liang SC, Latchman YE, Buhlmann JE et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33(10), 2706-2716 (2003).
167. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat. Rev. Immunol. 2(2), 116-126 (2002).
168. Ansari MJ, Salama AD, Chitnis T et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198(1), 63-69 (2003).
169. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1-/-mice as an efficient animal model of Type I diabetes. Proc. Natl Acad. Sci. USA 102(33), 11823-11828 (2005).
170. Carter LL, Fouser LA, Jussif J et al. PD-1: PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur. J. Immunol. 32(3), 634-643 (2002).
171. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27(4), 195-201 (2006).
172. Martin-Orozco N, Wang YH, Yagita H, Dong C. Cutting edge: programed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J. Immunol. 177(12), 8291-8295 (2006).
173. Keir ME, Liang SC, Guleria I et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203(4), 883-895 (2006).
174. Zhang Y, Chung Y, Bishop C et al. Regulation of T cell activation and tolerance by PDL2. Proc. Natl Acad. Sci. USA 103(31), 11695-11700 (2006).
175. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin. Cancer Biol. 16(1), 38-52 (2006).
176. He YF, Zhang GM, Wang XH et al. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J. Immunol. 173(8), 4919-4928 (2004).
177. Sznol M, Powderly J, Smith D et al. Safety and antitumor activity of biweekly MDX-1106 (anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J. Clin. Oncol. 28(Suppl. 15), 2506 (2010).
178. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
179. Chapoval AI, Ni J, Lau JS et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2(3), 269-274 (2001).
180. Prasad DV, Nguyen T, Li Z et al. Murine B7-H3 is a negative regulator of T cells. J. Immunol. 173(4), 2500-2506 (2004).
181. Sun M, Richards S, Prasad DVR, Mai XM, Rudensky A, Dong C. Characterization of mouse and human B7-H3 genes. J. Immunol. 168(12), 6294-6297 (2002).
182. Suh WK, Gajewska BU, Okada H et al. The B7 family member B7-H3 preferentially downregulates T helper type 1-mediated immune responses. Nat. Immunol. 4(9), 899-906 (2003).
183. Sun X, Vale M, Leung E, Kanwar J, Gupta R, Krissansen G. Mouse B7-H3 induces antitumor immunity. Gene Therapy 10(20), 1728-1734 (2003).
184. Luo L, Chapoval AI, Flies DB et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J. Immunol. 173(9), 5445-5450 (2004).
185. Prasad DV, Richards S, Mai XM, Dong C. B7-S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18(6), 863-873 (2003).
186. Sica GL, Choi IH, Zhu G et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18(6), 849-861 (2003).
187. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl Acad. Sci. USA 100(18), 10388-10392 (2003).
188. Rangachari M, Penninger JM. Negative regulation of T cell receptor signals. Curr. Opin. Pharmacol. 4(4), 415-422 (2004).
189. Nurieva RI, Zheng S, Jin W et al. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity 32(5), 670-680 (2010).
190. Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC, Lipkowitz S. Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 10(12), 2367-2377 (1995).
191. Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol 2(4), 294-307 (2001).
192. Paolino M, Thien CB, Gruber T et al. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions. J. Immunol. 186(4), 2138-2147 (2011).
193. Chiang YJ, Kole HK, Brown K et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403(6766), 216-220 (2000).
194. Bachmaier K, Krawczyk C, Kozieradzki I et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403(6766), 211-216 (2000).
195. Krawczyk C, Bachmaier K, Sasaki T et al. Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. Immunity 13(4), 463-473 (2000).
196. Chiang JY, Jang IK, Hodes R, Gu H. Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J. Clin. Invest. 117(4), 1029-1036 (2007).
197. Loeser S, Loser K, Bijker MS et al. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J. Exp. Med. 204(4), 879-891 (2007).
198. Wohlfert EA, Callahan MK, Clark RB. Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/-mice. J. Immunol. 173(2), 1059-1065 (2004).
199. Yokoi N, Komeda K, Wang HY et al. Cblb is a major susceptibility gene for rat type 1 diabetes mellitus. Nat. Genet. 31(4), 391-394 (2002).
200. Stromnes IM, Blattman JN, Tan X, Jeevanjee S, Gu H, Greenberg PD. Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice. J. Clin. Invest. 120(10), 3722-3734 (2010).
201. Hinterleitner R, Gruber T, Pfeifhofer-Obermair C et al. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PLoS ONE 7(9), e44295 (2012).
202. Perry WL, Hustad CM, Swing DA, O'Sullivan TN, Jenkins NA, Copeland NG. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat. Genet. 18(2), 143-146 (1998).
203. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14(1), 10-21 (2008).
204. Fang D, Elly C, Gao B et al. Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation. Nat. Immunol. 3(3), 281-287 (2002).
205. Parravicini V, Field AC, Tomlinson PD, Basson MA, Zamoyska R. Itch-/-alphabeta and gammadelta T cells independently contribute to autoimmunity in Itchy mice. Blood 111(8), 4273-7282 (2008).
206. Hartenstein B, Teurich S, Hess J, Schenkel J, Schorpp-Kistner M, Angel P. Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB. EMBO J. 21(23), 6321-6329 (2002).
207. Venuprasad K, Huang H, Harada Y et al. The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nat. Immunol. 9(3), 245-253 (2008).
208. Ho KC, Zhou Z, She YM, Chun A, Cyr TD, Yang X. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability [corrected]. Proc. Natl Acad. Sci. USA 108(12), 4870-4875 (2011).
209. Salah Z, Melino G, Aqeilan RI. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res. 71(5), 2010-2020 (2011).
210. Anandasabapathy N, Ford GS, Bloom D et al. GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 18(4), 535-547 (2003).
211. Seroogy CM, Soares L, Ranheim EA et al. The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J. Immunol. 173(1), 79-85 (2004).
212. Heissmeyer V, Rao A. E3 ligases in T cell anergy - turning immune responses into tolerance. Sci STKE 2004(241), pe29 (2004).
213. Soares L, Seroogy C, Skrenta H et al. Two isoforms of otubain-1 regulate T cell anergy via GRAIL. Nat. Immunol. 5(1), 45-54 (2004).
214. Su L, Lineberry N, Huh Y, Soares L, Fathman CG. A novel E3 ubiquitin ligase substrate screen identifies Rho guanine dissociation inhibitor as a substrate of gene related to anergy in lymphocytes. J. Immunol. 177(11), 7559-7566 (2006).
215. Lineberry N, Su L, Soares L, Fathman CG. The single subunit transmembrane E3 ligase gene related to anergy in lymphocytes (GRAIL) captures and then ubiquitinates transmembrane proteins across the cell membrane. J. Biol. Chem. 283(42), 28497-28505 (2008).
216. Schartner JM, Singh AM, Dahlberg PE, Nettenstrom L, Seroogy CM. Recurrent superantigen exposure in vivo leads to highly suppressive CD4+CD25+ and CD4+CD25-T cells with anergic and suppressive genetic signatures. Clin. Exp. Immunol. 155(2), 348-356 (2009).
217. Kriegel MA, Rathinam C, Flavell RA. E3 ubiquitin ligase GRAIL controls primary T cell activation and oral tolerance. Proc. Natl Acad. Sci. USA 106(39), 16770-16775 (2009).
218. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9(2), 194-202 (2007).
219. Rengarajan J, Mittelstadt PR, Mages HW et al. Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity 12(3), 293-300 (2000).
220. Zhu B, Symonds AL, Martin JE et al. Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease. J. Exp. Med. 205(10), 2295-2307 (2008).
221. Thomas RM, Chunder N, Chen C, Umetsu SE, Winandy S, Wells AD. Ikaros enforces the costimulatory requirement for IL2 gene expression and is required for anergy induction in CD4+ T lymphocytes. J. Immunol. 179(11), 7305-7315 (2007).
222. Wang J, Lee S, Teh CEY, Bunting K, Ma L, Shannon MF. The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. Int. Immunol. 21(3), 227-235 (2009).
223. Powell JD, Lerner CG, Ewoldt GR, Schwartz RH. The-180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J. Immunol. 163(12), 6631-6639 (1999).
224. Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol. 26, 133-169 (2008).
225. Martins GA, Cimmino L, Shapiro-Shelef M et al. Transcriptional repressor Blimp-1 regulates T cell homeostasis and function. Nat. Immunol. 7(5), 457-465 (2006).
226. Martins GA, Cimmino L, Liao J, Magnusdottir E, Calame K. Blimp-1 directly represses IL2 and the IL2 activator Fos, attenuating T cell proliferation and survival. J. Exp. Med. 205(9), 1959-1965 (2008).
227. Kallies A, Hawkins ED, Belz GT et al. Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance. Nat. Immunol. 7(5), 466-474 (2006).
228. Tzachanis D, Freeman GJ, Hirano N et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat. Immunol. 2(12), 1174-1182 (2001).
229. Wu Y, Borde M, Heissmeyer V et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126(2), 375-387 (2006).
230. Lee S-M, Gao B, Fang D. FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood 111(7), 3599-3606 (2008).
231. Zheng Y, Chaudhry A, Kas A. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses. Nature 458(7236), 351-356 (2009).
232. Koch MA. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 10(6), 595-602 (2009).
233. Chaudhry A, Rudra D, Treuting P et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Sci. Signal. 326(5955), 986 (2009).
234. Chung Y, Tanaka S, Chu F et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat. Med. 17(8), 983-988 (2011).
235. Fu W, Ergun A, Lu T et al. A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nat. Immunol. 13(10), 972-980 (2012).
236. Li B, Saouaf SJ, Samanta A, Shen Y, Hancock WW, Greene MI. Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Curr. Opin. Immunol. 19(5), 583-588 (2007).
237. Zheng Y, Josefowicz SZ, Kas A, Chu T-T, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445(7130), 936-940 (2007).
238. Marson A, Kretschmer K, Frampton GM et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445(7130), 931-935 (2007).
239. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693 (2007).
240. Fischer JJ, Toedling J, Krueger T, Schueler M, Huber W, Sperling S. Combinatorial effects of four histone modifications in transcription and differentiation. Genomics 91(1), 41-51 (2008).
241. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31(2), 89-97 (2006).
242. Wei G, Wei L, Zhu J et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 30(1), 155-167 (2009).
243. Schones DE, Cui K, Cuddapah S et al. Dynamic regulation of nucleosome positioning in the human genome. Cell 132(5), 887-898 (2008).
244. Bunting K, Wang J, Shannon MF. Control of interleukin-2 gene transcription: a paradigm for inducible, tissue-specific gene expression. Vit. Horm. 74, 105-145 (2006).
245. Bandyopadhyay S, Duré M, Paroder M, Soto-Nieves N, Puga I, Macián F. Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. Blood 109(7), 2878-2886 (2007).
246. Thomas R, Saouaf S, Wells A. Superantigen-induced CD4+ T cell tolerance is associated with DNA methylation and histone hypo-acetylation at cytokine gene loci. Genes Immun. 8(7), 613-618 (2007).
247. Avni O, Lee D, Macian F, Szabo SJ, Glimcher LH, Rao A. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat. Immunol. 3(7), 643-651 (2002).
248. Fields PE, Kim ST, Flavell RA. Cutting edge: changes in histone acetylation at the IL-4 and IFN-gamma loci accompany Th1/Th2 differentiation. J. Immunol. 169(2), 647-650 (2002).
249. Thomas RM, Gao L, Wells AD. Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J. Immunol. 174(8), 4639-4646 (2005).
250. Northrop JK, Thomas RM, Wells AD, Shen H. Epigenetic remodeling of the IL-2 and IFN-gamma loci in memory CD8 T cells is influenced by CD4 T cells. J. Immunol. 177(2), 1062-1069 (2006).
251. Lee PP, Fitzpatrick DR, Beard C et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15(5), 763-774 (2001).
252. Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat. Immunol. 4(3), 235-240 (2003).
253. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463(7282), 808-812 (2010).
254. Floess S, Freyer J, Siewert C et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5(2), e38 (2007).
255. Polansky JK, Kretschmer K, Freyer J et al. DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38(6), 1654-1663 (2008).
256. Baron U, Floess S, Wieczorek G et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells. Eur. J. Immunol. 37(9), 2378-2389 (2007).
257. Zhou X, Bailey-Bucktrout SL, Jeker LT et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10(9), 1000-1007 (2009).
258. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural FOXP3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc. Natl Acad. Sci. USA 106(6), 1903-1908 (2009).
259. Xu L, Kitani A, Fuss I, Strober W. Cutting edge: regulatory T cells induce CD4+ CD25-Foxp3-T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J. Immunol. 178(11), 6725-6729 (2007).
260. Rubtsov YP, Niec RE, Josefowicz S et al. Stability of the regulatory T cell lineage in vivo. Science 329(5999), 1667-1671 (2010).
261. Pesenacker AM, Bending D, Ursu S, Wu Q, Nistala K, Wedderburn LR. CD161 defines the subset of FOXP3+ T cells capable of producing pro-inflammatory cytokines. Blood 121(14), 2647-2658 (2013).
262. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA-4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18(2), 206-213 (2006).
263. Vicari AP, Vanbervliet B, Massacrier C et al. In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity. Novartis Found. Symp. 256, 241-254; discussion 254-269 (2004).